2019 was a great year for the average retail investor, continuing the epic bull market that began in March 2009. As we move into 2020, it looks like it has the potential to keep right on going.
The terrific economy that we've had has helped propel stocks to record highs. Unemployment remains at 50-year lows as real income adjusted for inflation is moving up for millions of Americans.
In a case like this, you'd think all you have to do from here on out is just coast on autopilot. After all, the bellwether S&P 500 was up roughly 28.9% for the year as of the close on Dec. 31.
But as impressive as all that sounds, you could do much better in 2020.
The S&P 500's numbers for the year are nothing compared to the gains Members of my monthly tech investing newsletter, the Nova-X Report, scored in 2019.
Indeed, our three best performers for the year more than doubled the S&P 500.
With that in mind, today I want to reveal three opportunities that made my Nova-X Report Members tons of cash - and show you how to get in on all the action...[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Three Superstars from the Nova-X Portfolio
Now, when I say my Nova-X Members had a great year in 2019, I'm in no way exaggerating. After all, we closed several stocks that tore the cover off the ball, in one case with combined gains of 237.5%.
But for this report, I'm only counting stocks that remained in the portfolio all year.
Either way, I believe this proves what I have been saying for years now. The road to wealth is paved with tech. And you can get to financial freedom a whole lot faster with a savvy veteran in your corner.
But you don't have to take my word for it. Just look at these stars of the Nova-X Report...
Nova-X 2019 Star No. 1: Medtech Leader Gains 82.6%
Truth be told, the returns for this leader are actually better than they sound. The stock didn't enter the portfolio until Jan. 28, 2019.
This stock also shows the importance of my unique Cowboy Split staggered entry system. Had we not literally doubled down after the stock sold off, we would have been stopped out with losses.
The company is top in the field of continuous glucose monitoring (CGM) for diabetics. Turns out it's a textbook example of savvy business execution. It has focused on one set of core products, and steadily ensured that more doctors, hospitals, and insurers understand the value of keeping diabetes in check through CGM.
It has recently added high-margin software and other products into the mix. Add it all up, and you get a firm that runs rings around the rest of the medtech sector, along with the whole S&P 500, which this stock beat by 186%.
Nova-X 2019 Star No. 2: Electronic Design Firm Gains 65.2%
Once again, Nova-X profits here are bigger than they sound. That's because back on Sept. 9, we took a free trade on this high-octane firm. By selling half, we got all our original capital back and are now playing on the house's money.
This high-octane firm is a leader in electronic design automation (EDA). The company's EDA tools are used by chip engineers who need to put a new design through grueling tests spanning thousands of hours.
If the chip can get through our aggressive leader's tough tests, it's ready to be dialed into today's most advanced computing systems and consumer devices.
Ironically, most investors have heard very little about the EDA market. And yet, Global Market Insights says the sector will be worth $14 billion by 2024. So, there are lots of profits still ahead for this stock.
Nova-X 2019 Star No. 3: 5G Supplier Gains 65%
This company has turned out to be one of the great ways to invest in the technology of 5G ultra-high-speed cellular. Make no mistake, this is a lucrative field.
MarketsandMarkets says firms will be spending $33.72 billion per year on 5G by 2026. And that may be a conservative estimate. Another prediction, by Research and Markets, pegs the 5G sector at $251 billion by 2025.
Our fast-moving firm is a great backend play on the whole sector. This exciting mid-cap player provides testing and measurement gear for electronics with a big emphasis on 5G products.
The firm boasts an impressive client roster. They need the company's gear to test and measure the quality of their products before releasing them.
Clients include all of the top 10 telecom equipment companies and all of the top 10 semiconductor suppliers. It also works with all the major electronics and aerospace firms, giving it lots of chances for big profits in 2020.
Add it all up, and you can see why I'm so happy with these 2019 market-crushing performances.
But as the saying goes, that's not all folks. I'm confident that when we close the books on 2020 a year from today, you will be getting another very upbeat report on the Nova-X portfolio of exciting winners.
And if you'd like to have these potentially market-crushing profit opportunities become a regular part of your portfolio, why not consider subscribing to the Nova-X Report?
Follow Money Morning on Facebook and Twitter.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.